Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

This study has been withdrawn prior to enrollment.
(Study Manager could not embark on it during the timeline.)
Information provided by:
Bayer Identifier:
First received: February 18, 2010
Last updated: April 12, 2012
Last verified: April 2012
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Condition Intervention
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Quality of life evaluated by several validated questionnaire [ Time Frame: Baseline, 3, 6, 9, 12 months (+/- 1 month) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Information about safety of Betaferon in routine clinical use [ Time Frame: Baseline, 3, 6, 9, 12 months (+/- 1 month) ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained

Enrollment: 0
Study Start Date: January 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
Patients receiving Betaferon according to routine clinical practice


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Tertiary hospital

Inclusion Criteria:

  • Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs
  • Patients who signed informed consent form

Exclusion Criteria:

  • Age lower than 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01071694

Korea, Republic of
Many locations, Korea, Republic of
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Global Medical Affairs Therapeutic area Head, Bayer HealthCare AG Identifier: NCT01071694     History of Changes
Other Study ID Numbers: 15110  Qolbet  BF1010KR 
Study First Received: February 18, 2010
Last Updated: April 12, 2012
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Bayer:
Multiple Sclerosis,
Interferon beta-1b,
Quality of life

Additional relevant MeSH terms:
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferon beta-1b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic processed this record on October 28, 2016